Status:
COMPLETED
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
Lead Sponsor:
Bayer
Conditions:
Male
Hypogonadism
Eligibility:
MALE
18+ years
Brief Summary
This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism. The benefit and safety of Nebido have alrea...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Eligibility Criteria
Inclusion
- Male hypogonadal patients eligible for long-term testosterone therapy who have newly been prescribed Nebido® in accordance with the terms of the marketing authorization
Exclusion
- Patients presenting with contraindications as stated in the product information
Key Trial Info
Start Date :
October 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
1493 Patients enrolled
Trial Details
Trial ID
NCT00410306
Start Date
October 1 2006
End Date
July 1 2010
Last Update
September 24 2010
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Australia
2
Many Locations, Austria
3
Many Locations, Bulgaria
4
Many Locations, Colombia